Results 51 to 60 of about 15,879 (168)

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

Smart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin, Rui Peng, Guangshuai Zhang, Si Yan, Jin Xiao, Zishu Liu, Ziyu Tan, Qingqing Xie, Shangjie Li, Wei Luo, Xiaohe Xiao   +10 more
wiley   +1 more source

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

Recent progress on the development of hydrogel‐based microneedles for transdermal drug delivery

VIEW, EarlyView.
This study provides a comprehensive and up‐to‐date analysis of recent progress in HMN technology, covering fundamental transdermal delivery mechanisms and design principles, biomaterials used in HMN fabrication, drug loading and release strategies, and emerging therapeutic applications.
Mohammad Muhtasim Ittisaf, Salman Farsi Taharat, Md. Sadek Miah, Hasan Tasnim Salehin, M. Azam Ali, Shoeb Ahmed   +5 more
wiley   +1 more source

Ablative radiotherapy in castration‐resistant prostate cancer

BJU International, EarlyView.
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Tobias Hölscher, Fabian Lohaus, Lydia Koi, Jörg Kotzerke, Sebastian Hoberück, Christian Thomas, Angelika Borkowetz, Steffen Löck, Mechthild Krause, Esther G.C. Troost   +9 more
wiley   +1 more source

Evaluation of triplet therapy combined with robot‐assisted cytoreductive prostatectomy for high‐volume metastatic prostate cancer: a multicentre randomised controlled trial protocol

BJU International, EarlyView.
Background Prostate cancer (PCa) is the second most common cancer in men. For patients with high‐volume metastatic PCa (mPCa) who are fit for docetaxel, a triplet therapy regimen consisting of androgen deprivation therapy (ADT), chemotherapy, and an androgen receptor pathway inhibitor (ARPI) is recommended.
Xiangwei Yang, Zhuobin He, Jian Chen, Hanqi Lei, Binyuan Yan, Linze Chen, Hong Liu, Jun Pang   +7 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Mapping the Radiopharmaceutical Therapy Landscape for Prostate Cancer: Insights Into Global Clinical Trial Trends and Future Directions

Med Research, EarlyView.
Zhiwu Dong, Sixiang Yan, Xiaodong Liu, Peng Gu   +3 more
wiley   +1 more source

The role of macrophage migration inhibitory factor (MIF) in the pathogenesis and progression of cardiovascular disease

British Journal of Pharmacology, EarlyView.
Abstract Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury.
Shreya Mahabhashyam, James Harris, Jürgen Bernhagen, Antony Vinh, Katrina M. Mirabito Colafella   +4 more
wiley   +1 more source

Efficacy, Safety, and Cost-Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Study. [PDF]

Prostate
ABSTRACT Background The introduction of novel androgen receptor signaling inhibitors (ARSIs) has substantially transformed the systemic treatment landscape for non‐metastatic castration‐resistant prostate cancer (nmCRPC). Unfortunately, ARSI therapy is associated with considerable adverse events (AEs) and high medical costs.
Asanuma H, Fujita N, Kato S, Kawashima Y, Shinohara M, Tabata R, Yoneyama F, Tanaka R, Oishi T, Miura H, Togashi K, Okita K, Horiguchi H, Tanaka T, Noro D, Suzuki Y, Sato S, Ohyama C, Hatakeyama S.   +18 more
europepmc   +2 more sources